| Line | All comers |
|---|
| Early / localised | 1 |
| Locally advanced | 1 |
| Advanced, first line | 1 |
| Second line | 1 |
| Other settings | 2 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Localised, resectable | Wide resection including involved nerves where needed, with neck dissection for node-positive disease, followed by postoperative radiotherapy to the bed and nerve pathways. | | NCCN · Category 2A | 93 |
Locally advanced
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Unresectable or inoperable | Definitive radiotherapy; carbon-ion or proton therapy where available (COSMIC, Heidelberg; fast-neutron series). | | ESMO salivary gland cancer guideline 2022 | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Slow-growing metastatic disease | Observation with scans every few months; stereotactic radiotherapy or resection for isolated symptomatic metastases. | | NCCN · Category 2A | 40 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Progressive metastatic disease | Lenvatinib or axitinib (phase 2 evidence); clinical trials preferred. | | NCCN · Category 2A | 98 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Chemotherapy | Cisplatin with doxorubicin and cyclophosphamide, or single agents, for symptomatic disease after kinase inhibitors; responses are uncommon. | | NCCN · Category 2B | 82 |
| All comers | Trials | MYB-directed REM-422, HG146 and NOTCH inhibitors for NOTCH1-mutant disease. | | | 26 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.